保利片
医学
药丸
冲程(发动机)
人口
心理干预
初级预防
重症监护医学
发达国家
二级预防
固定剂量组合
环境卫生
传统医学
阿司匹林
内科学
药理学
疾病
机械工程
精神科
工程类
作者
Michael Brainin,Yvonne Teuschl,Sheila Cristina Ouriques Martins
出处
期刊:Stroke
[Ovid Technologies (Wolters Kluwer)]
日期:2022-08-01
卷期号:53 (8): 2695-2701
被引量:5
标识
DOI:10.1161/strokeaha.122.037313
摘要
A polypill-type strategy for primary prevention was first published at the turn of the century and advised that a multi-ingredient pill applied to an adult population would prevent up to 80% of cardiovascular and stroke events. Such a pill should contain small doses of antihypertensives, lipid-lowering drugs, and some nutrients. The startling increase of the global stroke burden has led to a revival of this concept and the propagation of a population-based prevention strategy. Recent cardiovascular fixed-dose combination trials have shown a significant effect in reducing not only blood pressure and cholesterol levels but also in reducing cardiovascular and stroke events. In most of the studies, the study population was for secondary prevention and the total number of strokes was small. Nevertheless, it is now clear that a large proportion of primary prevention must take this path. It is especially promising when combined with community health workers interventions for modifying risk behavior. While a polypill-type approach seems most efficacious in underserved regions of high-income countries as well as in low- and middle-income countries, it seems to have a large overall effect in spite of some problems with nonadherence or potential side effects. It should be available and affordable for large target populations. Larger phase 4 studies are under way.
科研通智能强力驱动
Strongly Powered by AbleSci AI